Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
出版年份 2018 全文链接
标题
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
作者
关键词
-
出版物
Frontiers in Oncology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-10-04
DOI
10.3389/fonc.2018.00423
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IDO takes a blow
- (2018) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
- (2018) Lilla Hornyák et al. Frontiers in Immunology
- Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.
- (2018) Kathryn Cecilia Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.
- (2018) Yousef Zakharia et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer
- (2017) K.A. Ahmed et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Neoadjuvant systemic therapy for regionally advanced melanoma
- (2017) James W. Jakub et al. JOURNAL OF SURGICAL ONCOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
- (2016) T.C. Gangadhar et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- A phase I study of indoximod in patients with advanced malignancies
- (2016) Hatem H. Soliman et al. Oncotarget
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
- (2015) Michael Platten et al. Frontiers in Immunology
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
- (2008) K. Ino et al. CLINICAL CANCER RESEARCH
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
- (2008) Ke Pan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
- (2008) A. J. Muller et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started